QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
NASDAQ:VXRT

Vaxart Stock Competitors

$6.35
+0.58 (+10.05%)
(As of 12/7/2021 04:00 PM ET)
Add
Compare
Today's Range
$5.92
$6.40
50-Day Range
$5.77
$8.02
52-Week Range
$4.86
$24.90
Volume
4.73 million shs
Average Volume
11.48 million shs
Market Capitalization
$796.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.19

Vaxart (NASDAQ:VXRT) Vs. RLAY, IOVA, TIL, KYMR, ALLO, VALN, IBRX, BCRX, EDIT, and RVMD

Should you be buying Vaxart stock or one of its competitors? The main competitors of Vaxart include Relay Therapeutics (RLAY), Iovance Biotherapeutics (IOVA), Instil Bio (TIL), Kymera Therapeutics (KYMR), Allogene Therapeutics (ALLO), Valneva (VALN), ImmunityBio (IBRX), BioCryst Pharmaceuticals (BCRX), Editas Medicine (EDIT), and Revolution Medicines (RVMD). These companies are all part of the "biological products, except diagnostic" industry.

Vaxart vs.

Vaxart (NASDAQ:VXRT) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, community ranking, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Iovance Biotherapeutics has a net margin of 0.00% compared to Vaxart's net margin of -5,414.56%. Vaxart's return on equity of -36.10% beat Iovance Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Vaxart -5,414.56% -36.10% -30.69%
Iovance Biotherapeutics N/A -45.34% -38.91%

Iovance Biotherapeutics received 220 more outperform votes than Vaxart when rated by MarketBeat users. Likewise, 78.33% of users gave Iovance Biotherapeutics an outperform vote while only 66.67% of users gave Vaxart an outperform vote.

CompanyUnderperformOutperform
VaxartOutperform Votes
304
66.67%
Underperform Votes
152
33.33%
Iovance BiotherapeuticsOutperform Votes
524
78.33%
Underperform Votes
145
21.67%

Vaxart currently has a consensus price target of $13.75, indicating a potential upside of 116.54%. Iovance Biotherapeutics has a consensus price target of $38.20, indicating a potential upside of 103.41%. Given Vaxart's higher possible upside, analysts plainly believe Vaxart is more favorable than Iovance Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vaxart
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
Iovance Biotherapeutics
0 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.83

Vaxart has higher revenue and earnings than Iovance Biotherapeutics. Vaxart is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vaxart$4.05 million196.77-$32.22 million-$0.54-11.76
Iovance BiotherapeuticsN/AN/A-$259.58 million-$2.06-9.12

Vaxart has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

In the previous week, Vaxart had 10 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 13 mentions for Vaxart and 3 mentions for Iovance Biotherapeutics. Vaxart's average media sentiment score of 0.22 beat Iovance Biotherapeutics' score of 0.16 indicating that Vaxart is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vaxart
2 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Iovance Biotherapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

27.8% of Vaxart shares are held by institutional investors. 3.1% of Vaxart shares are held by insiders. Comparatively, 9.9% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Vaxart beats Iovance Biotherapeutics on 9 of the 17 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VXRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Vaxart (NASDAQ:VXRT) vs. Its Competitors

TypeVaxartBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$796.90M$3.75B$4.96B$7.91B
Dividend YieldN/A2.12%2.05%2.56%
P/E Ratio-11.769.6022.3123.43
Price / Sales196.772,989.972,427.47276.02
Price / CashN/A99.8261.93204.50
Price / Book3.905.046.156.53
Net Income-$32.22M$2.41M$96.04M$154.44M
7 Day Performance-20.23%-3.22%-1.82%-0.32%
1 Month Performance-4.94%-13.75%-11.90%-8.92%
1 Year Performance-17.53%-4.92%9.63%27.26%

Vaxart Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RLAY
Relay Therapeutics
2.2848 of 5 stars
$29.50
+5.2%
$51.25
+73.7%
-46.2%$3.19B$82.65M0.002,020Gap Up
IOVA
Iovance Biotherapeutics
1.6833 of 5 stars
$18.78
+9.9%
$38.20
+103.4%
-60.7%$2.95BN/A-9.12241News Coverage
Gap Up
TIL
Instil Bio
2.1164 of 5 stars
$22.33
+11.3%
$30.40
+36.1%
N/A$2.88B$140K0.00150High Trading Volume
KYMR
Kymera Therapeutics
2.1157 of 5 stars
$55.80
+5.8%
$76.43
+37.0%
-1.7%$2.87B$34.03M-33.0275Gap Up
ALLO
Allogene Therapeutics
2.5944 of 5 stars
$18.75
+8.2%
$36.23
+93.2%
-48.8%$2.67BN/A-9.97265Short Interest ↑
Gap Up
VALN
Valneva
1.2682 of 5 stars
$48.00
+1.0%
$36.00
+25.0%
N/A$2.52B$126.02M0.00500Gap Down
IBRX
ImmunityBio
1.8716 of 5 stars
$6.02
+5.5%
$25.00
+315.3%
N/A$2.39B$110K0.00171Upcoming Earnings
BCRX
BioCryst Pharmaceuticals
2.2014 of 5 stars
$12.21
+8.4%
$20.20
+65.4%
+83.3%$2.18B$17.81M-9.61246
EDIT
Editas Medicine
2.1351 of 5 stars
$30.97
+9.4%
$57.27
+84.9%
-18.6%$2.12B$90.73M-9.56235Gap Up
RVMD
Revolution Medicines
2.3998 of 5 stars
$27.35
+6.0%
$35.83
+31.0%
-36.6%$2.02B$42.98M-11.54125
NSTG
NanoString Technologies
1.8731 of 5 stars
$40.73
+6.6%
$67.50
+65.7%
-35.3%$1.86B$117.32M-16.69579
VCEL
Vericel
1.8548 of 5 stars
$39.71
+5.6%
$53.00
+33.5%
+49.1%$1.86B$124.18M-3,971.00273
SRNE
Sorrento Therapeutics
1.9917 of 5 stars
$5.95
+11.8%
$28.67
+381.8%
-34.1%$1.82B$39.99M-4.84502News Coverage
CCCC
C4 Therapeutics
2.3579 of 5 stars
$36.78
+3.1%
$48.50
+31.9%
+5.0%$1.79B$33.19M0.0099
ALEC
Alector
2.6214 of 5 stars
$21.94
+9.6%
$40.33
+83.8%
+36.3%$1.78B$21.10M-42.19171Gap Up
ATRA
Atara Biotherapeutics
1.8121 of 5 stars
$17.89
+5.1%
$30.33
+69.6%
-30.9%$1.58BN/A-4.94437
KRYS
Krystal Biotech
2.2464 of 5 stars
$71.03
+4.9%
$115.33
+62.4%
+19.4%$1.58BN/A-26.2175Gap Up
High Trading Volume
INBX
Inhibrx
2.1331 of 5 stars
$40.45
+9.6%
$53.00
+31.0%
+0.2%$1.54B$12.89M-19.5488
CHRS
Coherus BioSciences
2.0648 of 5 stars
$17.96
+1.9%
$25.75
+43.4%
-7.0%$1.38B$475.82M-5.72317
RGNX
REGENXBIO
2.7373 of 5 stars
$31.96
+0.5%
$58.25
+82.3%
-16.0%$1.37B$154.57M-6.18306Gap Up
REPL
Replimune Group
2.3865 of 5 stars
$29.10
+6.6%
$55.00
+89.0%
-41.9%$1.36BN/A-15.00152
IMCR
Immunocore
1.5082 of 5 stars
$31.30
+11.9%
$54.75
+74.9%
N/A$1.35B$38.67M0.002,020News Coverage
ALVR
AlloVir
2.2998 of 5 stars
$19.36
+1.9%
$46.67
+141.0%
-59.4%$1.26B$170K0.0053
SGMO
Sangamo Therapeutics
1.8881 of 5 stars
$8.47
+3.1%
$23.00
+171.5%
-17.8%$1.23B$118.19M-6.67413
OCGN
Ocugen
1.8914 of 5 stars
$5.97
+9.5%
$7.90
+32.3%
+1,643.1%$1.19B$42.62M0.0015Gap Up
RUBY
Rubius Therapeutics
2.0998 of 5 stars
$13.11
+5.9%
$26.33
+100.9%
+75.9%$1.18BN/A-6.18204
ITOS
iTeos Therapeutics
2.5348 of 5 stars
$33.03
+2.6%
$46.25
+40.0%
+9.3%$1.17BN/A113.9062Insider Selling
Short Interest ↓
Gap Up
PCVX
Vaxcyte
1.6065 of 5 stars
$21.52
+6.2%
N/A-35.9%$1.14BN/A-12.0258
CRBU
Caribou Biosciences
1.9848 of 5 stars
$18.78
+9.9%
$30.60
+62.9%
N/A$1.13BN/A0.002,021
HUMA
Humacyte
2.4917 of 5 stars
$10.55
+2.0%
$17.25
+63.5%
N/A$1.09BN/A0.00N/A
ICVX
Icosavax
1.825 of 5 stars
$25.31
+11.3%
$48.57
+91.9%
N/A$988.15MN/A0.002,021
IMVT
Immunovant
1.9667 of 5 stars
$7.99
+4.3%
$16.00
+100.3%
-84.2%$918.85MN/A-6.2968
SRRK
Scholar Rock
2.3865 of 5 stars
$25.94
+2.7%
$65.00
+150.6%
-38.5%$910.70M$15.40M-7.61119Gap Up
MGTX
MeiraGTx
2.4514 of 5 stars
$20.09
+15.1%
$26.50
+31.9%
+25.8%$892.98M$15.56M-10.92219News Coverage
Gap Up
High Trading Volume
IPSC
Century Therapeutics
1.7048 of 5 stars
$16.06
+2.2%
$36.00
+124.2%
N/A$877.53MN/A0.00102Gap Up
SOPH
SOPHiA Genetics
1.7 of 5 stars
$13.75
+5.5%
$23.00
+67.3%
N/A$870.90M$28.40M0.00N/AGap Up
BCAB
BioAtla
2.5333 of 5 stars
$23.64
+4.9%
$65.20
+175.8%
N/A$870.80M$430K0.0036Insider Selling
News Coverage
Gap Up
MESO
Mesoblast
1.9317 of 5 stars
$6.51
+9.8%
$13.50
+107.4%
-63.5%$844.60M$7.46M-8.35102High Trading Volume
AGEN
Agenus
2.1598 of 5 stars
$3.23
+6.2%
$11.00
+240.6%
-9.0%$829.56M$88.17M-26.92359
GLUE
Monte Rosa Therapeutics
1.3915 of 5 stars
$17.49
+5.5%
$32.00
+83.0%
N/A$813.39MN/A0.0060
TNYA
Tenaya Therapeutics
1.7048 of 5 stars
$19.51
+1.7%
$36.00
+84.5%
N/A$805.39MN/A0.002,021
GRTS
Gritstone bio
2.3998 of 5 stars
$11.52
+7.0%
$22.33
+93.9%
+257.0%$783.22M$4.04M-9.00169News Coverage
CGEM
Cullinan Oncology
2.5333 of 5 stars
$17.46
+3.3%
$51.75
+196.4%
N/A$762.74MN/A0.0024Gap Up
FMTX
Forma Therapeutics
1.9931 of 5 stars
$15.57
+4.2%
$60.17
+286.4%
-65.7%$738.10M$100.56M-4.76105Analyst Upgrade
Gap Down
IMTX
Immatics
1.7 of 5 stars
$11.43
+5.2%
$27.00
+136.2%
+0.6%$719.05M$35.70M0.002,020
STRO
Sutro Biopharma
2.0531 of 5 stars
$15.50
+0.3%
$32.00
+106.5%
-31.3%$717.19M$42.72M-5.27192
OMGA
Omega Therapeutics
1.6681 of 5 stars
$14.90
+3.2%
$29.50
+98.0%
N/A$711.85MN/A0.002,021Gap Up
BLUE
bluebird bio
2.3698 of 5 stars
$9.95
+0.6%
$18.07
+81.6%
-78.7%$697.57M$250.73M-0.781,213Analyst Upgrade
ADAP
Adaptimmune Therapeutics
1.9531 of 5 stars
$3.89
+7.7%
$8.40
+115.9%
-19.7%$607.63M$3.96M-3.932,020Gap Up
TALS
Talaris Therapeutics
2.1181 of 5 stars
$14.62
+7.1%
$29.50
+101.8%
N/A$604.61MN/A0.0082Short Interest ↑
Gap Up
High Trading Volume
This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.